fbpx

Recently Diagnosed or Relapsed? Stop Looking For a Miracle Cure, and Use Evidence-Based Therapies To Enhance Your Treatment and Prolong Your Remission

Multiple Myeloma an incurable disease, but I have spent the last 25 years in remission using a blend of conventional oncology and evidence-based nutrition, supplementation, and lifestyle therapies from peer-reviewed studies that your oncologist probably hasn't told you about.

Click the orange button to the right to learn more about what you can start doing today.

Multiple Myeloma By the Numbers

Share Button

“Survival (Multiple Myeloma) varies depending upon a host of factors: the stage of disease, biology including cytogenetic abnormalities and response to therapy.

I think it was Mark Twain who said “there are lies, damn lies, and statistics. If you have been diagnosed with Multiple Myeloma, the info below can put this incurable blood cancer in perspective.

I am both a long-term MM survivor and MM cancer coach. I am supremely skeptical of MM statistics because I was diagnosed at the age of 34, failed conventional therapies after only 35 months and have lived in complete remission since 1999.

I have excerpted multiple myeloma statistics from the ginormous list linked below to provide newly diagnosed MMers with what I believe are the most relevant MM stats for you to learn.

Please keep in mind that the MM stats below are based on conventional MM oncology. While conventional chemo regimens such as Velcade, Revlimid and Dexamethasone can be essential to managing your MM, my experience and research provide a loud and clear statement for evidence-based non-conventional therapies such as nutrition, supplementation, lifestyle therapies and more.

 

Let me know if you have any questions by leaving a comment below.

Hang in there,

David Emerson

  • MM Survivor
  • MM Cancer Coach
  • Director PeopleBeatingCancer

Recommended Reading:


Multiple myeloma       From Standard Of Care

  • “Estimated 30,000 new cases diagnosed in 2016 and an estimated 12,650 deaths.
  • 5-year survival nearly 50%.
  • Second most common hematologic cancer after NHL.
  • MM represents 1.8% of all new cancer cases.
  • Projected to be the fastest rising hematologic cancer by 2030.
  • Increasing numbers of patients with MM due to an aging population.
  • Ranks as the 15th most common type of cancer in the United States.
  • Lifetime risk for developing myeloma is estimated at 0.7%
  • Accounts for 10% of malignant hematologic neoplasms.
  • Estimated that approximately 96,000 patients are living with multiple myeloma.
  • Incidence and mortality 2-fold among Blacks than Whites.
  • Twice as common in blacks compared with whites and this is due to a higher prevalence of monoclonal gammopathy of undetermined significance in blacks.
  • Accounts or 2% of all cancer deaths in the U.S.
  • Median age at diagnosis 65-70 years.
  • The median age at death is 75 years, with mortality rate increasing as age increases.
  • Fewer than 4% of patients younger than 45 years.
  • 75% of men and 79% of affected women are older than 70 years.
  • 37% of patients younger than 65 years of age.
  • 26% are diagnosed by between ages 65 and 74 years.
  • 37% 75 years or older at diagnosis.
  • If untreated, median survival for symptomatic patients is approximately 12 months.
  • Survival varies depending upon a host of factors: the stage of disease, biology including cytogenetic abnormalities and response to therapy.
  • In patients under 60 years of age median 10-year survival approximately 30% (Kumar SK et al).
  • Unfortunately, approximately 25% of patients have a median survival of 2 years or less.
  • There has been an increase in the incidence in patients younger than 55 years of age over the past several decades.
  • Male to female ratio approximately 3 to 2.
  • Does not occur in children.
  • Approximately 2 to 3% of myeloma cases have no detectable M protein and is referred to as non-secretory myeloma.
  • Initially, the disease is confined to the bone marrow, but over time it can grow and affect the peripheral blood, pleural fluid, lymph nodes, organs, and skin.
  • Chromosome abnormalities detected with cytogenetics or fluorescence in situ hybridization in more than 90% of cases and include deletions, trisomies, and translocations.
  • The median survival time of approximately 7 years, with 20% of patients living for more than 10 years.
  • The natural progression of disease results in end-organ damage, including severe hematologic complications as plasma cells, replace bone marrow and kidney damage stems from the deposition of myeloma monoclonal light change in the kidney.
  • Poor prognosis associated with decreased serum albumin, increased beta 2 microglobulin, the presence of abnormal cytogenetics, increased interleukin 6, increased C reactive protein, high lactate dehydrogenase, extramedullary disease, insufficiency, high serum free light chains, abnormal kappa/lambda ratio, increased plasma cell labeling index, cytogenetic changes and the presence of circulating plasma cells

Leave a Comment:

7 comments
Add Your Reply